Why the study?
Does FA-PEG-AL/HCPT NPs improve tumor suppression efficacy and reduce side effects compared to free HCPT in tumor xenograft models?
Does FA-PEG-AL/HCPT NPs improve tumor suppression efficacy and reduce side effects compared to free HCPT in tumor xenograft models?
A novel lignin-based nanoparticle platform for anticancer drug delivery demonstrated superior tumor suppression and reduced side effects compared to free drug in preclinical models.
Lignin-based NPs may aid HCPT delivery in animal models; leaves open clinical translation and human trials.
The clinical applications of natural anticancer drugs are being restricted by poor water solubility, fast clearance in the circulation, lack of targeting to tumor cells, and poor tissue penetration. To address these problems, in this study, we developed a novel lignin-based targeted polymeric nanoparticles (NPs) platform, folic acid-polyethylene glycol-alkaline lignin conjugates (FA-PEG-AL), via self-assembly for delivery of anticancer drug (hydroxyl camptothecin, HCPT). These lignin-based nanoparticles had moderate particle size (∼150 nm) with a narrow size distribution (PDI < 0.1), exhibited excellent biocompatibility, high drug loading efficiency (∼24.2 wt % of HCPT), prolonged blood circulation time (∼7-fold of free HCPT), and enhanced cellular uptake (∼5-fold of free HCPT). Besides, the drug biodistribution study confirmed preferred accumulation of FA-PEG-AL/HCPT NPs in tumor tissue. Subsequent tumor xenograft test revealed superior tumor suppression efficacy and reduced side effects of FA-PEG-AL/HCPT NPs compared with free HCPT. Therefore, the prepared lignin-based FA-PEG-AL/HCPT NPs would be a promising candidate for anticancer drugs delivery.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: